Comparative Pharmacology
Head-to-head clinical analysis: AMINOCAPROIC ACID IN PLASTIC CONTAINER versus CYKLX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOCAPROIC ACID IN PLASTIC CONTAINER versus CYKLX.
AMINOCAPROIC ACID IN PLASTIC CONTAINER vs CYKLX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminocaproic acid is a lysine analog that binds to plasminogen and prevents its conversion to plasmin, thereby inhibiting fibrinolysis and stabilizing clots. It also inhibits plasmin directly at high doses.
CYKLX is a selective phosphodiesterase 4 (PDE4) inhibitor, increasing intracellular cyclic adenosine monophosphate (cAMP) levels and reducing pro-inflammatory cytokine production.
4-5 g IV over 1 hour followed by 1 g/h IV for 8 hours or until bleeding is controlled; max 30 g/24h.
100 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours in patients with normal renal function. In end-stage renal disease, half-life may be prolonged to 7-10 hours.
Terminal half-life: 12 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min).
Primarily renal (approximately 80-90% excreted unchanged in urine via glomerular filtration).
Renal: 70% unchanged; biliary/fecal: 30% as metabolites.
Category C
Category C
Antifibrinolytic
Antifibrinolytic